Small molecule inhibitors of METTL3 catalytic activity have previously demonstrated direct anti-tumour efficacy in models of acute myeloid leukemia (AML). Here we present pre-clinical data showing that the orally bioavailable small molecule METTL3 inhibitor STC-15 inhibits cancer growth and induces anti-cancer immunity.

2023年5月1日 · STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors, establishing a data …

2024年11月28日 · stc-15是首个进入人体临床评估的rme抑制剂。 临床前研究表明，STC-15可通过涉及抗癌免疫反应的机制抑制肿瘤生长。 这包括干扰素信号的变化以及与T细胞检查点阻断的建设性相互作用。

Storm Therapeutics has developed potent and selective METTL3 inhibitors, including STC-15, which is in clinical development (clinical trial NCT05584111). Here, we explore pharmacological inhibition of METTL3 as monotherapy or in combination with …

2023年1月25日 · Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models; STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors

2024年11月26日 · STC-15 targets METTL3, an RNA methyltransferase involved in the regulation of innate immune responses and tumor immune evasion. STC-15 marks the first RME inhibitor to enter human clinical evaluation. Preclinically, STC-15 has been shown to inhibit tumor growth through mechanisms involving anticancer immune responses.

STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.

STORM’s lead clinical program STC-15 is a first-in-class inhibitor of RNA modification and is the first ever RNA methyltransferase inhibitor to enter clinical development. STC-15 is an oral small molecule that inhibits METTL3, an RNA methyltransferase implicated in oncology and …

Cells treated with STC-15 accumulated double-stranded RNA suggesting that activation of IFN signalling is triggered by innate pattern recognition sensors. In an in vitro co-culture system, STC-15 demonstrated strong and dose-dependent enhancement of PBMC-mediated killing of …

2020年10月24日 · sTC-15是一种口服型小分子METTL3抑制剂，用于治疗急性髓细胞性白血病以及其他实体瘤和血液癌症。 该公司利用其药物发现能力，以及专门针对RNA表观遗传学开发的分析技术，来生成高效的METTL3和其他RNA修饰酶的选择性小分子抑制剂。 STORM Therapeutics首席执行官Keith Blundy说：“sTC-15是一种高效且选择性的METTL3抑制剂，急性髓细胞性白血病患者将被纳入最初的临床试验中”。 原始出处： …